Search
retifanlimab (Zynyz)
Indications:
- metastatic or recurrent locally advanced Merkel cell carcinoma
Mechanism of action:
- targets checkpoint inhibitor PD-1
- blocks PD-1 interaction with PD-1 ligands PD-L1 & PD-L2
- suppresses tumor growth
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
antineoplastic monoclonal antibody
References
- Grignani G et al
545 A phase 2 study of retifanlimab in patients with advanced or metastatic
merkel cell carcinoma (MCC) (POD1UM-201)
Journal for ImmunoTherapy 2023, 9(S2)
Not indexed in PubMed
https://jitc.bmj.com/content/9/Suppl_2/A574